Study of Milnacipran for the Treatment of Fibromyalgia
Completed
Forest Laboratories
Phase 3
2004-11-01
Antidepressants of all varieties represent a common form of therapy for many chronic states
including fibromyalgia. The majority of antidepressants increase the levels of serotonin or
norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and
serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.
Study of Milnacipran for the Treatment of Fibromyalgia
Completed
Cypress Bioscience, Inc.
Phase 3
2006-04-01
The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a
dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with
fibromyalgia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
